活性维生素D预防糖尿病前期成人肌少症:DPVD辅助随机对照试验
BACKGROUND: Observational studies show inverse associations between serum 25-hydroxyvitamin D concentrations and sarcopenia incidence; however, it remains unclear whether treatment with vitamin D prevents its development.…
要点
- 两组不良事件发生率无差异,安全性可接受。
核心结论
- 活性维生素D(艾地骨化醇)治疗可能通过增加骨骼肌体积和力量预防糖尿病前期人群肌少症发生。
- 艾地骨化醇组肌少症发生率显著低于安慰剂组,且不良事件发生率两组无差异。
研究设计与样本
- 随机、双盲、安慰剂对照、多中心试验,作为DPVD辅助研究在日本32家诊所和医院开展。
主要发现
- 两组不良事件发生率无差异。
临床怎么用
- 对于糖尿病前期成人,可考虑评估肌少症风险,艾地骨化醇可能作为预防肌少症的一种干预选择。
- 该干预可能通过增加骨骼肌体积和力量降低跌倒风险,但需结合个体情况综合判断。
局限性
- 本研究为DPVD辅助研究,研究对象为日本糖尿病前期成人,结论外推至其他人群需谨慎。
- 肌少症诊断采用生物电阻抗分析而非双能X线吸收法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Observational studies show inverse associations between serum 25-hydroxyvitamin D concentrations and sarcopenia incidence; however, it remains unclear whether treatment with vitamin D prevents its development. We aimed to assess whether treatment with active vitamin D (eldecalcitol [0·75 μg per day]) can reduce the development of sarcopenia among adults with prediabetes. METHODS: This randomised, double-blind, placebo-controlled, multicenter trial as an ancillary study was conducted at 32 clinics and hospital sites in Japan. Participants were assigned (1:1) by using a central randomisation method in which a randomisation list was made for each hospital separately using a stratified permuted block procedure. The primary endpoint was sarcopenia incidence during 3 years in the intention-to-treat population defined as weak handgrip strength (<28 kg for men and <18 kg for women) and low appendicular skeletal muscle index (<7·0 kg/m2 for men and <5·7 kg/m2 for women in bioelectrical impedance analysis). Although the usual criterion of hypercalcaemia was 10·4 mg/dL (2·6 mmol/L) or higher, hypercalcaemia that was enough to discontinue the study was defined as 11·0 mg/dL or higher. This study is registered with the UMIN clinical trials registry, UMIN000005394. FINDINGS: A total of 1094 participants (548 in the eldecalcitol group and 546 in the placebo group; 44·2% [484 of 1094] women; mean age 60·8 [SD 9·2] years) were followed up for a median of 2·9 (IQR 2·8-3·0) years. Eldecalcitol treatment as compared with placebo showed statistically significant preventive effect on sarcopenia incidence (25 [4·6%] of 548 participants in the eldecalcitol group and 48 [8·8%] of 546 participants in the placebo group; hazard ratio 0·51; 95% CI 0·31 to 0·83; p=0·0065). The incidence of adverse events did not differ between the two groups. INTERPRETATION: We found that treatment with eldecalcitol has the potential to prevent the onset of sarcopenia among people with prediabetes via increasing skeletal muscle volume and strength, which might lead to a substantial risk reduction of falls. FUNDING: Kitakyushu Medical Association. TRANSLATION: For the Japanese translation of the abstract see Supplementary Materials section.
引用
- Kawahara T, Suzuki G, Mizuno S, et al. Active vitamin D treatment in the prevention of sarcopenia in adults with prediabetes (DPVD ancillary study): a randomised controlled trial. Lancet Healthy Longev. 2024. PMID: 38437855. doi:10.1016/S2666-7568(24)00009-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。